PharmaMar Begins a Phase I Study of PM1183 in Japan for the Treatment of Solid Tumors

Monday, November 28, 2016 Mental Health News
Email Print This Page Comment bookmark
Font : A-A+

MADRID, November 28, 2016 /PRNewswire/ --

PharmaMar (MCE:PHM) has announced the start of an open-label, multicenter,

Phase I study in Japan to evaluate the recommended dose (RD) of PM1183 (lurbinectedin) in patients with certain types of unresectable/advanced solid tumors.

     (Logo: http://photos.prnewswire.com/prnh/20150203/727958-b

)

The main objective of the study is to determine the recommended dose of PM1183 in Japanese patients. Furthermore, the secondary objective will be to evaluate the safety profile, to obtain preliminary information on the antitumor activity along with pharmacokinetic characteristics of PM1183 in Japanese patients when compared to Caucasians.

The study population has to be patients born in Japan or descendants from both Japanese parents that suffer disease progression according to the Response Criteria in Solid Tumors (RECIST v1.1).

As Dr Arturo Soto, director of Clinical Development of PharmaMar's Oncology Business Unit, explains "Three clinical sites in Japan will participate in the trial; the number of patients that are to be included will depend on the tolerability and activity observed in PM1183 and the dose level required to identify the recommended dose in this population".

Contact: Paula Fernández, Media Relations Manager +34-638-79-62-15 [email protected] Investor Relations +34-914444500

SOURCE PharmaMar



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store